News | Brachytherapy Systems | October 31, 2018

Prostate Brachytherapy Shows Low Incidence of Short-Term Complications

Eighty-two percent of men in single-institution study reported no complications at four months post-procedure

Prostate Brachytherapy Shows Low Incidence of Short-Term Complications

October 31, 2018 — A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related complications within four months of treatment is less than 20 percent. All patients were treated at Fox Chase Cancer Center in Philadelphia.

Brachytherapy is a form of internal radiation therapy in which doctors implant permanent or temporary radioactive sources into the prostate. It confines the radiation to the tumor and reduces radiation exposure to the surrounding healthy tissues. It can be administered either as permanent low dose-rate (LDR) implant, or as temporary high dose-rate (HDR) implant. In this study, 97 men received HDR and 485 received LDR.

Of the 582 men studied, 477, or 82 percent reported no complications. The most common complication within four months was lower urinary tract symptoms, which affected 8.4 percent of the patients.

Douglas Lee, DO, a radiation oncology resident at Fox Chase, led the study and presented it at an oral session at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Oct. 21-24 in San Antonio, Texas.

“There have been several studies of long-term complications associated with brachytherapy, but this is one of the largest analyses of the near-term procedural complications,” Lee said. “Our findings add to the data showing that brachytherapy is safe for men treated at a single institution with expertise in this treatment.”

In the United States, prostate cancer is the most commonly diagnosed cancer in men. Nearly 200,000 cases are diagnosed in each year. It is frequently treatable, especially when diagnosed at earlier stages.

Read more about late-breaking clinical trials presented at ASTRO 2018.

For more information: www.astro.org

Related Content

Isoray to Spotlight Cesium-131 Advances at ASTRO Annual Meeting
News | Brachytherapy Systems | September 13, 2019
Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131 brachytherapy at the...
Akesis Galaxy SRS System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | September 13, 2019
The Akesis Galaxy, a gamma stereotactic radiosurgery system (SRS) with continuous 360-degree rotational technology, has...
Philips Showcases Integrated Radiation Oncology Portfolio at ASTRO 2019
News | Radiation Oncology | September 13, 2019
Philips will showcase its integrated radiation oncology portfolio at the American Society of Radiation Oncology (ASTRO...
RefleXion Highlights Novel Approach to Radiotherapy at ASTRO 2019

The RefleXion X1 Machine without the Gantry Cover. The patented technology incorporates PET imaging data, which enables tumors to continuously signal their location. Image courtesy of Reflexion Medical.

News | Radiation Therapy | September 12, 2019
Therapeutic oncology company RefleXion Medical announced it will showcase the RefleXion X1 Machine at the American...
IBA Dosimetry Releases myQA Machines Software at ASTRO 2019
Technology | Quality Assurance (QA) | September 12, 2019
IBA Dosimetry GmbH announced the launch of the new enhanced myQA Machines 2019 software environment at the upcoming...
ASTRO 2019 to Feature Clinical Experience and Patient Outcomes With Viewray MRIdian
News | Image Guided Radiation Therapy (IGRT) | September 11, 2019
ViewRay Inc. announced that the company's MRIdian and MRIdian Linac magnetic resonance imaging (MRI)-guided radiation...
RadCalc 3D Monte Carlo Calculations for Photons Begins Beta Testing
News | Radiation Therapy | September 11, 2019
RadCalc version 7.1 with the Monte Carlo 3-D module has been released for beta testing to members of the beta testing...
Accuray to Display Motion Synchronization Cancer Treatment Technologies at ASTRO 2019
News | Radiation Therapy | September 09, 2019
Accuray announced that it will showcase its motion-synchronization cancer treatment technologies at the upcoming 2019...
New Guideline Clarifies Role of Radiation Therapy in Pancreatic Cancer Treatment
News | Radiation Therapy | September 05, 2019
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use...
First Clinical Monte Carlo Photon Dose Planning Conducted in RayStation
News | Treatment Planning | September 05, 2019
Heidelberg University Hospital, Germany, has treated its first patient using Monte Carlo photon dose planning in...